Australian Clinical Labs Limited (ASX: ACL) - Share Price
Current share price for ACL : $2.210 0.07 (3.07%)+
Australian Clinical Labs (ACL), an ASX-listed company, is an Australian private provider of pathology services. The Company's NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients.
ACL General Information +
| ASX Code | ACL |
| Website | http://clinicallabs.com.au |
| Industry/Sector | Health Care Services |
| Market Cap ($M) | 412 |
| ACL Share Price | $2.210 |
| Day High | $2.300 |
| Day Low | $2.205 |
| Last Close | $2.280 |
| ACL Share Price Movement | $0.07 ( 3.07% ) |
Prices as at 11:05, 8 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Australian Clinical Labs Limited (ACL) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Result | 3.75¢ | 100% | 12 Mar 2026 | 31 Mar 2026 | - | - | - |
| HFResult | 9¢ | 100% | 1 Sep 2025 | 23 Sep 2025 | - | - | - |
| Result | 3.5¢ | 100% | 27 Mar 2025 | 16 Apr 2025 | - | - | - |
See all dividends from Australian Clinical Labs Limited (ACL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Australian Clinical Labs Limited (ACL) price-sensitive announcements
ACL - Appointment of new Group CEO
Australian Clinical Labs Limited (ACL) announced the appointment of Greg Horan as its new
Australian Clinical Labs Limited (ACL)
28 May 2026 | 9:06 AM
28 May 2026 | 9:06 AM
ACL - Class action proceedings
On April 21, 2026, Australian Clinical Labs Limited (ACL) announced that it has been serve
Australian Clinical Labs Limited (ACL)
21 Apr 2026 | 8:14 AM
21 Apr 2026 | 8:14 AM
ACL - CEO contract update
Australian Clinical Labs Limited announced that their Group CEO and Executive Director, Me
Australian Clinical Labs Limited (ACL)
16 Feb 2026 | 9:22 AM
16 Feb 2026 | 9:22 AM
ACL - ACL 1H26 financial results investor presentation
Australian Clinical Labs Limited (ACL) reported its 1H26 financial results, highlighting i
Australian Clinical Labs Limited (ACL)
16 Feb 2026 | 8:10 AM
16 Feb 2026 | 8:10 AM
Australian Clinical Labs Limited (ACL) Recent ASX Announcements
ACL Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | $34.84 | $18.10 | -3.40% | 17.60 | 12.50 | 3.90% | 100.0% |
| 2024A | $37.69 | $18.70 | 22.20% | 14.80 | 12.00 | 4.30% | 100.0% |
| 2023A | $30.99 | $15.30 | -83.40% | 23.90 | 14.00 | 3.80% | 100.0% |
ACL Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Australian Clinical Labs Limited (ACL) | $427M | -0.0336 | 0.0000 | 0.0000 | 12.6449 | 0.0000 | 0.0000 | 5.46% | 0.00% | 0.00% |
| Healius Limited (HLS) | $280M | -4.7068 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Integral Diagnostics Limited (IDX) | $769M | -1.3095 | 0.5666 | 0.1667 | 26.8930 | 17.1667 | 14.7143 | 3.16% | 3.88% | 3.40% |
| Sonic Healthcare Limited (SHL) | $10,646M | 0.0625 | 0.1134 | 0.1484 | 20.1874 | 18.1313 | 15.7883 | 4.97% | 5.08% | 5.13% |
ACL Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.20 | 12.60 | 2.61 | 0.00 |
| Market | 0.28 | 13.00 | 1.15 | 0.59 |
| Sector | 0.69 | 23.20 | 1.62 | 2.64 |
ACL Directors
| Name | Position | Start Date |
|---|---|---|
| Ms Melinda Leigh McGrath | Chief Executive Officer, Executive Director | 19 Dec 2020 |
| Ms Christine Nildra Bartlett | Non-Executive Director | 23 Aug 2023 |
| Mr Mark Haberlin | Non-Executive Director | 28 Apr 2021 |
| Ms Sarah Butler | Non-Executive Director | 1 Feb 2025 |
| Dr Amandeep Kaur Hansra | Non-Executive Director | 1 Jul 2026 |
| Mr Stephen Patrick Roche | Non-Executive Director, Non-Executive Chairman | 20 Jun 2025 |
Australian Clinical Labs Limited (ACL) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 19 Feb 2026 | BUTLER, Sarah | Buy | Indirect Shares | 22,617 | $2.210 | $49,983.570 |
| 28 Oct 2025 | ROCHE, Stephen | Buy | Direct Shares | 70,000 | $2.770 | $193,900.000 |
| 28 Feb 2024 | BARTLETT, Christine | Buy | Indirect Shares | 20,000 | $2.358 | $47,154.000 |
See all changes in directors' interest & trades for Australian Clinical Labs Limited (ACL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ACL Management
| Name | Position |
|---|---|
| Matthew Cordingley | Chief Financial Officer |
| Eleanor Padman | Company Secretary |
ACL Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Australian Clinical Labs Limited (ACL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 29,764,987 (15.16%) | Allan Gray Australia Pty Ltd |
| 14,877,241 (7.58%) | State Street Australia Ltd |
| 14,312,777 (7.29%) | Commonwealth Bank of Australia and its related bodies corporate |
| 14,114,260 (7.19%) | Superannuation and Investments HoldCo Pty Ltd and its related bodies |
| 14,114,260 (7.19%) | Comet Asia Holdings II Pte Ltd |
| 14,007,561 (7.13%) | Mitsubishi UFJ Financial Group, Inc. |
| 14,007,561 (7.13%) | First Sentier Investors Holdings Pty Limited |
ACL Calendar of Events
| Date | Event |
|---|---|
| 15 February 2027 | Report (Interim) |
| 18 September 2026 | Report (Annual) |
| 25 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
